Donor and recipient genetic polymorphisms modulate tacrolimus pharmacokinetics during voriconazole co-therapy: a drug–drug interaction study in liver transplant recipients
In summary, Donor and recipient <i>CYP3A4/5</i> and <i>CYP2C19</i> genotypes jointly influence TAC pharmacokinetics during VRC co-therapy. Genotype-guided dosing strategies integrating both donor and recipient genotypes may improve TAC dosing precision. TAC dose reinstatement may be deferred until day six following VRC discontinuation to avoid overexposure.
Authors
- K. Tang
- Lei Li (ORCID: https://orcid.org/0000-0001-8723-3461)
- Jiali Li (ORCID: https://orcid.org/0009-0006-3550-5473)
- Jieling Li
- Xiaoman Liu (ORCID: https://orcid.org/0000-0001-9879-9540)
- Pan Chen
- Xiao Chen
- Jie Chen
- Xiaobin Lin
- Yanzhe Xia
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Therapeutic Advances in Drug Safety
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1177/20420986261420282
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00